Table 4.
Sensitivity and specificity of antituberculosis drug resistance predictions based on whole-genome sequence compared with the MICs of phenotypic AST of each antituberculosis drug
| Susceptible isolates (phenotypic AST) | Resistant isolates (phenotypic AST) | Isolates without genotypic AST resistance marker | Isolates with genotypic AST resistance marker | Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|---|---|---|---|
| Isoniazid* | 88 | 808 | 95 | 801 | 98·8% (98·5–99·0) | 96·6% (95·2–97·9) |
| Rifampicin* | 114 | 780 | 77 | 817 | 99·5% (99·3–99·7) | 64·0% (61·0–67·1) |
| Kanamycin | 564 | 331 | 549 | 346 | 96·1% (95·4–96·8) | 95·0% (94·4–95·7) |
| Amikacin | 714 | 181 | 709 | 186 | 97·2% (96·4–98·1) | 98·6% (98·3–98·9) |
| Capreomycin | 600 | 29 | 592 | 37 | 93·1% (90·0–96·3) | 98·3% (98·0–98·7) |
| Moxifloxacin | 681 | 216 | 686 | 211 | 88·9% (87·4–90·3) | 97·2% (96·8–97·6) |
| Levofloxacin† | 628 | 96 | 615 | 109 | 94·8% (93·3–97·6) | 97·1% (96·7–97·6) |
| Ethambutol | 142 | 81 | 166 | 57 | 100% (100) | 40·1% (37·4–42·9) |
| Pyrazinamide | 80 | 132 | 85 | 127 | 87·9% (86·0– 89·8) | 83·8% (81·0–86·5) |
MIC=minimum inhibitory concentration. AST=antimicrobial susceptibility testing.
*
Due to potential laboratory error, four samples with Ser450Leu mutation in rpoB (rifampicin) and two samples with Ser315Thr in katG (isoniazid) were excluded from the analysis.
†
17 samples were tested at MIC 1·5 mg/L (previous critical concentration) and were excluded from the analysis.